Press release
Galectin Inhibitor Therapeutics - Pipeline Analysis 2019
Download the sample Report @ https://www.pharmaproff.com/request-sample/1209
Many studies have demonstrated role of galectins in the pathogenesis of various diseases including malignant, fibrotic and inflammatory diseases; hence, emerges as an attractive target for the therapeutic of various diseases. Galectin-3 inhibitors has shown positive clinical results for the treatment of acute lymphoblastic leukemia. Thus, providing several opportunities to the companies for the development of galectin-based therapies for the treatment of multiple human diseases.
Get the detailed analysis @ https://www.pharmaproff.com/report/galectin-inhibitor-therapeutics
Galectin Therapeutics Inc. is in the process of developing GR-MD-02 as a galectin-3 inhibitor for the treatment of fibrosis, cancer and plaque psoriasis. It is also being studied in combination with Yervoy and Keytruda, for the treatment of cancer. GlycoMimetics Inc., and Galecto Biotech AB are some other companies having pipeline of galectin inhibitors.
Request for customization @ https://www.pharmaproff.com/request-customization/1209
The report provides a comprehensive understanding of the pipeline activities covering all drug candidates under various stages of development, with detailed analysis of pipeline and clinical trials. Pipeline analysis of drugs by phases includes product description and development activities including information about clinical results, designations, collaborations, licencing, grants, technology and others.
About Us:
Pharma Proff, is a frontline market intelligence and consulting solutions provider catering to the information and data needs of burgeoning sectors across the world, including pharmaceutical and healthcare. With meticulously curated research reports on the industry landscape, we empower companies in the healthcare and pharmaceutical sectors to make informed business decisions and base their marketing strategies with astuteness.
Contact:
Pharma Proff
Toll-free: +1-888-778-7886 (USA/Canada)
International: +1-347-960-6455
Email: enquiry@pharmaproff.com
Web: https://www.pharmaproff.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Galectin Inhibitor Therapeutics - Pipeline Analysis 2019 here
News-ID: 1646100 • Views: …
More Releases from Pharma Proff
Interleukin-6 (IL-6) Inhibitors Analysis, Clinical Trails and Developments
Interleukin-6 (IL-6) inhibitors currently exhibit a proliferating pipeline with 25+ therapeutic candidates.
IL-6 is a cytokine encoded by IL-6 gene, which helps in the maturation of B cells and is actively involved in the inflammatory response. The IL-6 protein is primarily produced at the sites of acute and chronic inflammation, where it is secreted into the serum and brings a transcriptional inflammatory response through IL-6? receptor. This protein is assumed to…
Retinitis Pigmentosa Therapeutics Analysis, Clinical Trials and Other Developmen …
Retinitis pigmentosa therapeutics currently exhibits a proliferating pipeline with 25+ therapeutic candidates.
Retinitis pigmentosa (RP) is a group of hereditary disorders that lead to the breakdown and loss of cells in the retina. Mutation in genes encoding the proteins required by retinal cells for their proper functioning, results in occurrence of RP. The disease results in partial vision loss during the earlier stage of the disease, which may lead to complete…
Probiotics Therapeutics -Pipeline Analysis 2018, Clinical Trials & Results, Pate …
Probiotics are live microorganisms that produces beneficial effects in human gut. Probiotics can be taken as a dietary supplement. They prevent diarrhoea and help to reduce the symptoms of irritable bowel syndrome.
Download the sample report at: https://www.pharmaproff.com/request-sample/1189
Probiotics comprise of a variety of microorganisms belonging to the Lactobacillus and Bifidobacterium groups. The only yeast probiotic that has proven to be effective is Saccharomyces boulardii. According to researchers, probiotics are effective in…
Niemann-Pick Disease Type C (NPC) Therapeutics Pipeline to Witness Significant G …
Niemann-Pick disease is divided into four main types: type A, type B, type C1, and type C2. These types are classified on the basis of genetic cause and signs and symptoms of the disease. NPC is identified as a rare genetic disorder in which the body is unable to transport cholesterol and lipids inside the cells. This causes accumulation of these substances within various tissues of the body. These substances…
More Releases for Galectin
Galectin-9 Antibody Market is expected to grow at USD 560 million by 2034, Drive …
" The global Galectin-9 antibody market is valued at approximately $200 million in 2024 and is projected to reach around $560 million by 2034, reflecting a robust Compound Annual Growth Rate (CAGR) of about 10.5% during the forecast period from 2025 to 2034. This growth is primarily driven by the increasing prevalence of autoimmune diseases and cancers, combined with rising investments in research and development initiatives."
Exactitude Consultancy., Ltd. released a…
Liver Cirrhosis Market Forecasted for Strong Growth from 2025 to 2032 | Madrigal …
Latest Report, titled "Liver Cirrhosis Market" Trends, Share, Size, Growth, Opportunity and Forecast 2025-2032, by CoherentMI offers a comprehensive analysis of the industry, which comprises insights on the market analysis. The report also includes competitor and regional analysis, and contemporary advancements in the market.
The Global liver cirrhosis market is estimated to be valued at USD 1.41 Billion in 2024 and is expected to reach USD 2.03 Billion by 2031, growing…
Galectin 3 Market Top Companies Growth Analysis and Evolutionary Trends by 2032
In 2023, the expected market size for Galectin 3 was 7.53 billion US dollars. It is anticipated that the market for galectin 3 would increase from 7.94 (USD billion) in 2024 to 12.1 (USD billion) in 2032. It is anticipated that the Galectin 3 Market would expand at a compound annual growth rate (CAGR) of around 5.41% from 2024 to 2032.
Market Trend: The Galectin-3 Market is experiencing significant growth, driven…
Shaping the Future: Circulating Galectin Inhibitor Market's Forward-Thinking Tre …
This Market study covers the Global and Regional "Circulating Galectin Inhibitor Market" with an in-depth analysis of the overall growth prospects in the market. Furthermore, it sheds light on the comprehensive competitive landscape of the global market. The Circulating Galectin Inhibitor Market report further offers a dashboard overview of leading companies encompassing their successful marketing strategies, market contribution, and recent developments in both historic and present contexts. The report also…
Global Galectin 3 Market Size,Share,Depth Survey,2022-2028| Angion Biomedica Cor …
Los Angeles, United States October 2022,- The research study presented here is a brilliant compilation of different types of analysis of critical aspects of the global Galectin 3 market. It sheds light on how the global Galectin 3 market is expected to grow during the course of the forecast period. With SWOT analysis and Porter's Five Forces analysis, it gives a deep explanation of the strengths and weaknesses of the global…
Global Galectin Inhibitor Therapeutics Market 2020:Comprehensive Study By Key Pl …
Global galectin inhibitor therapeutics market is expected to gain market growth in the forecast period of 2020 to 2027. Data Bridge Market Research analyses the market is growing at a healthy CAGR in the above-mentioned research forecast period. Emerging markets and huge investment in research and development are the factors responsible for the growth of this market.
This galectin inhibitor therapeutics report works as a reputable source of information to offer…
